Adial Pharmaceuticals Appoints David Rubenstein, M.D., Ph.D., as Chief Scientist to Advance its Colon-Targeted AhR Agonist, AT177, for Ulcerative Colitis
Adial Pharmaceuticals appointed Dr. David Rubenstein as Chief Scientist to lead development of AT177, its oral colon-targeted AhR agonist for ulcerative colitis. Rubenstein previously led tapinarof (VTAMA), the first FDA-approved AhR agonist, through development, approval and commercialization at Dermavant Sciences.
Key figures
- Drug Name
- AT177
- Phase Of Trial
- IND-enabling (preclinical)
- First in human trials planned
- 2027
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.